两种非诺贝特治疗高脂血症的成本-效果分析.pdfVIP

Strait Pharmaceutical Journal Vol 24 No.2 2012 ·药物经济学· 两种非诺贝特治疗高脂血症的成本-效果分析 应国烽1. 陈梅莉2 (1.浙江省绍兴第二医院药剂科绍兴 312000;2. 浙江省绍兴市人民医院药剂科绍兴 312007) 摘要z 目的 评价口服拌诺贝特片与非诺贝特缓锋胶囊治疗高脂血症的成本效果。方法 运用药物经济学成本分析的方法将高血脂门诊志 者共 100 例，随机分为两组，分别给予非诺贝特片与非诺贝特缓释胶囊，30 天为一疗程。根据药物经济学计算两种治疗方案的成本放采分析。 结果 非诺贝特片组与非话贝特生是得胶囊组成本分别为 220.7 与 329.6 元，有放率分别为 88% 与闪%，成本效果比分别为 250.8 与 350.6; 缓 锋舷金组相对于普通片剂组的增量成本-效果比为 1815。结论 普通片剂用药方案治疗高脂血症较佳。 关键词:非诺贝材;成本-效果分析;高脂血症;药物经济学 中图分类号:R407.77 文献标识码:A 文章编号: 1006-3765(2012) -02-0245-03 Cost-effectiveness Analysis of Two Therapeutic Schemes by Fenofibrate for Hyperlipidemia 1 2 YING Guo-feng , CHEN Mei- 1i (1. Zheijiang Shaoxing Second Hospital , Shaoxing , 312000 , China; 2. Shaoxing people s hospital , Shaoxing 312000 , China) ABSTRACT:OBJECTIVE To evaluate the economic efficiency of Fenofibrate tablets and Fenofibrate sustained release capsules in treatment of hyperlipidemia. METHODS 100 out-patients clinic with hyperlipidemia were di- vided into two groups: Fenofibrate tablets group and Fenofibrate sustained release capsules group. Data was evalu- ated using the pharmacoeconimic cost-effectiveness analysis. RESULTS For Group Fenofibrate tablets and Fenofibrate sustained release capsules , the costs were 220.7 and 329.6 yuan , respectively; the total effective rates were 88 % and 94 %, respectively; the cost-effectiveness ratios were 250.8 and 350.6. respectively. The increme仔 tal cost-effectiveness ratios of Group Fenofibrate sustained release capsules were 1815 as against Group Fenofibrate tablets.CONCLUSION Group Fenofibrate tablets is preferable for hyperlipidemia between the two groups. KEY WORDS: Fenofibrate; Cost-effectiven四s analysis; Hyperlipidemia; Harmacoeconomics 随着社会发展，目前心脑血管疾病已成为威胁人类健康 人患者。经过改善生活方式和饮食治疗3 个月以上无效的高 的第一杀手。而高脂血症(血脂异常)作为心脑血管疾病的主 胆固醇血症( II a 型)，内源性高甘油三醋血症，单纯型